Chongqing Zhifei Biological Products Co., Ltd.

Chongqing Zhifei Biological Products Co., Ltd. is a China-based vaccine company headquartered in Chongqing. Founded in 1995 and listed on the Shenzhen Stock Exchange in 2010, the company operates China's largest commercial vaccine distribution network. Revenue of RMB 8.958 billion (≈US$1.25 billion, 2025), reflecting a 65.61% decline driven by the structural collapse of the imported HPV vaccine market. R&D spending reached RMB 1.436 billion (16.03% of revenue) across 41 pipeline programs.

Business Overview

Zhifei Biological occupies a unique position in China's vaccine ecosystem: the bridge between multinational pharmaceutical giants and China's 1.4 billion population. For over a decade, the company served as the exclusive China distributor for Merck's Gardasil 9-valent HPV vaccine—the world's bestselling vaccine by revenue—building a sales force that reaches 30,000+ grassroots vaccination points. However, 2025 marked a structural inflection point as domestic competitors (Wantai Biological, Walvax) launched locally-manufactured HPV vaccines at significantly lower prices, triggering an 85%+ collapse in Gardasil procurement and a historic RMB 14.728 billion net loss.

The path forward centers on proprietary R&D: 41 pipeline programs spanning TB vaccines, meningococcal conjugates, pneumococcal vaccines, and COVID-19 recombinant protein vaccines, with 5 products filed for market approval and a stated target of 25% self-developed product revenue by 2027.

Key Strengths

The 30,000+ vaccination point commercial network is China's most extensive vaccine distribution asset—an irreplaceable channel for any company seeking nationwide vaccine access. The revised Merck agreement eliminating minimum purchase obligations fundamentally de-risks the balance sheet from inventory impairment recurrence. R&D intensity at 16.03% of revenue signals serious commitment to innovation rather than perpetual distribution dependence. Three technology platforms (viral, bacterial, recombinant protein) provide broad modality coverage. Five products submitted for market approval create near-term revenue diversification catalysts.

Challenges & Outlook

The RMB 14.728 billion annual loss and RMB 14.128 billion asset impairment represent the worst financial result in Chinese vaccine industry history, testing investor confidence and management credibility. Revenue dependency on agency distribution remains extreme at 85.74%, and the transition to self-developed products will require 2-3 years to meaningfully impact the top line. Chinese domestic HPV vaccine manufacturers (Wantai, Walvax) have damaged the pricing umbrella permanently, eliminating the high-margin distribution model. Achieving the 2027 self-developed revenue target of 25% requires flawless execution on manufacturing scale-up and regulatory approvals—against a backdrop of intense domestic competition and compressed pricing across all vaccine categories.